[PDF][PDF] Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

…, L Scaltriti, D Katsaros, D Priolo, G Scambia - Journal of Clinical …, 2008 - academia.edu
… Gabriella Ferrandina, Manuela Ludovisi, Domenica Lorusso, Sandro Pignata, Enrico
Breda, Antonella Savarese, Pietro Del Medico, Laura Scaltriti, Dionyssios Katsaros …

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

…, M Wan, L Dubeau, G Scambia… - … journal of cancer, 1995 - Wiley Online Library
The AKT2 gene is one of the human homologues of v‐akt, the transduced oncogene of the
AKT8 virus, which induces lymphomas in mice. In previous studies, AKT2, which codes for a …

The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer …

S Pignata, G Scambia, F Raspagliesi, V Murgia… - 2016 - ascopubs.org
5505 Background: A longer PFI is associated with better outcomes in patients with OC. It has
long been hypothesized that artificially prolonging PFI by introducing a non-platinum based …

[HTML][HTML] Italian consensus conference on management of uterine sarcomas on behalf of SIGO (Societa'italiana di Ginecologia E Ostetricia)

…, AC Testa, GF Zannoni, G Scambia… - European Journal of …, 2020 - Elsevier
Background Uterine sarcomas are very rare tumours with different histotypes, molecular
features and clinical outcomes; therefore, it is difficult to carry out prospective clinical trials, and …

Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma

…, AA Lissoni, M Signorelli, G Scambia… - American journal of …, 2014 - Elsevier
Objective The purpose of this study was to explore in greater depth the outcomes of the Italian
randomized trial investigating the role of pelvic lymphadenectomy in clinical early stage …

A randomized multicenter phase III study comparing weekly versus every 3 week carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC) …

S Pignata, G Scambia, R Lauria, F Raspagliesi… - 2013 - ascopubs.org
LBA5501 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT)
on Saturday, June 1, 2013, and in the Annual Meeting Proceedings online supplement …

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …

…, N Colombo, JI Weberpals, A Clamp, G Scambia… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-…

Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial

…, AA Lissoni, M Signorelli, G Scambia… - JNCI: Journal of the …, 2008 - academic.oup.com
Background Pelvic lymph nodes are the most common site of extrauterine tumor spread in
early-stage endometrial cancer, but the clinical impact of lymphadenectomy has not been …

[HTML][HTML] A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms

…, A Burges, R Kimmig, G Scambia… - … England Journal of …, 2019 - Mass Medical Soc
Background Systematic pelvic and paraaortic lymphadenectomy has been widely used in the
surgical treatment of patients with advanced ovarian cancer, although supporting evidence …

Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis

…, M Liberati, J Vecchiet, L Nappi, G Scambia… - American journal of …, 2020 - Elsevier
Objective The aim of this systematic review was to report pregnancy and perinatal outcomes
of coronavirus spectrum infections, and particularly coronavirus 2019 (COVID-19) disease …